Literature DB >> 17684645

Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin.

M H P Pavan1, P E N F Velho, A G Vigani, F L Gonçalves, F H Aoki.   

Abstract

We reported one case of human immunodeficiency virus and hepatitis C virus co-infected patient who presented a significant improvement of human papillomavirus (HPV) lesions during the treatment of chronic hepatitis using peg-interferon alfa-2b and ribavirin.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17684645     DOI： 10.1590/s1413-86702007000300017

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN： 1413-8670            Impact factor:   1.949


  5 in total

1.  Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin.

Authors:  Theodore R Miller; Jeffrey J Weiss; Norbert Bräu; Douglas T Dieterich; Alicia Stivala; Monica Rivera-Mindt
Journal:  J Neurovirol       Date:  2016-11-28       Impact factor: 2.643

2.  Multimethod assessment of baseline depression and relationship to hepatitis C treatment discontinuation.

Authors:  Jeffrey J Weiss; Sarah Prieto; Norbert Bräu; Douglas T Dieterich; Sue M Marcus; Alicia Stivala; Jack M Gorman
Journal:  Int J Psychiatry Med       Date:  2018-01-03       Impact factor: 1.210

Review 3.  Interferons as therapeutic agents for infectious diseases.

Authors:  Scott J Bergman; McKenzie C Ferguson; Cathy Santanello
Journal:  Infect Dis Clin North Am       Date:  2011-12       Impact factor: 5.982

Review 4.  Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance.

Authors:  Stéphanie Beaucourt; Marco Vignuzzi
Journal:  Curr Opin Virol       Date:  2014-05-19       Impact factor: 7.090

Review 5.  Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.

Authors:  Maryam Dadar; Sandip Chakraborty; Kuldeep Dhama; Minakshi Prasad; Rekha Khandia; Sameer Hassan; Ashok Munjal; Ruchi Tiwari; Kumaragurubaran Karthik; Deepak Kumar; Hafiz M N Iqbal; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2018-11-12       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.